The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J06 | Immune sera and immunoglobulins | |
3
|
J06B | Immunoglobulins | |
4
|
J06BD | Antiviral monoclonal antibodies | |
5
|
J06BD10 |
| Active Ingredient |
|---|
|
Clesrovimab is a fully human immunoglobulin G1 kappa (IgG1κ) neutralising monoclonal antibody with a triple amino acid substitution (YTE) in the Fc region which increases binding to the neonatal Fc receptor leading to an extended serum half-life. Clesrovimab provides passive immunity by targeting the RSV outer membrane fusion (F) protein to prevent viral entry into cells. |
| Document | Type | Information Source | |
|---|---|---|---|
| ENFLONSIA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ENFLONSIA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.